Trial Profile
A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Patritumab Deruxtecan (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 29 Sep 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 20 Mar 2023 According to a Daiichi Sankyo company media release, updated results and new data including first presentation of data from a cohort of patients with EGFR-mutated metastatic non-small cell lung cancer presented during two Presidential Sessions at the Japanese Society of Medical Oncology (#JSMO2023) Annual Meeting.
- 20 Mar 2023 Results of pooled analysis between cohorts and new data presented in a Daiichi Sankyo company media release.